[Adriamycin, VM 26, cyclophosphamide and prednisone (AVmCP) combination in the therapy of disseminated lymphoreticulosarcoma (Stages or topographical forms III and IV].
This work presents the results obtained on 24 patients with disseminated lymphosarcoma and reticulosarcoma (stage III and IV) with a cyclic combination chemotherapy which combines adriamycin, epipodophyllotoxin (VM 26), cyclophosphamide and prednisone. The complete remission rate is 58 p.cent of the patients who entered the trial, the response rate is 75 p.cent. Tolerance of the regimen is good in general from the hematological point of view.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009366:Neoplasm Seeding; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011241:Prednisone / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D013713:Teniposide / Q000627:therapeutic use*
D004317:Doxorubicin; D003520:Cyclophosphamide; D013713:Teniposide; D011034:Podophyllotoxin; D011241:Prednisone
Combinaison d'adriamycine, de VM26, de cyclophosphamide et de prednisone (AVmCP) pour la chimiothérapie des lymphoréticulosarcomes disséminés (stades ou formes topographiques III et IV)